Jump to content
RemedySpot.com

Dr. De Meirleir's Breakthrough Research and Recommendations for CFS (leaky gut)

Rate this topic


Guest guest

Recommended Posts

hola, my llmd talked of research by Dr. De Meirleir regarding leaky gut. i

searched web and found this article. doc wants me to have this set of new

blood tests. i'll try to post more info when able.

deep peace,

kendra

-----Original Message-----

http://www.gulfwarvets.com/ubb/ultimatebb.php?ubb=get_topic;f=12;t=000068

Dr. Kenny De Meirleir’s Breakthrough Research and Recommendations for CFS

Testing & Treatment by Editor ImmuneSupport.com

08-18-2006 Kenny De Meirleir, MD, PhD, is a member of ProHealth’s Scientific

Advisory Board. As described in the following article, Dr. De Meirleir

reports that his research indicates Chronic Fatigue Syndrome patients can be

differentiated from healthy people with 99 percent accuracy based on a test

for the presence of “low molecular weight” RNase L in the blood. He says the

weight of LMW RNase L molecules found in the blood of CFS patients is less

than half that of normal RNase L molecules. (And this holds true for

individuals with several other illnesses, including Fibromyalgia.) Increased

symptom severity correlates directly with increased levels of LMW RNase L.

Additionally, though Dr. De Meirleir emphasizes that each patient’s profile

is unique, he says his research indicates that CFS patients tend to fall

into three groups with different test profiles and treatments. Based on the

results of six tests, he reports he has been able to predict patients’

symptoms with 95 percent accuracy while the remaining 5 percent had overlap

features.

_________

Highlights of Dr. Kenny De Meirleir’s Lecture on “Advances in ME/CFS Testing

and Treatment,” presented in Calgary, Alberta, on April 2, 2006

by Marjorie van de Sande

Note

Dr. De Meirleir is a world renowned researcher and is professor of

Physiology and Internal Medicine at Free University of Brussels in Belgium.

Dr. De Meirleir recently published his 600th peer-reviewed paper. He is

co-editor of Chronic Fatigue Syndrome: A Biological Approach, co-editor of

the Journal of Chronic Fatigue Syndrome, and reviewer for more than 10 other

medical journals. Dr. De Meirleir was one of four international experts on

the panel that developed the Canadian Consensus Document for ME/CFS. He

assesses/treats 3,000 to 4,000 ME/CFS patients annually.

Normal Response to Infectious Agents

Numerous infectious agents can trigger ME/CFS. Infectious agents that invade

cells release ribonucleic acid (RNA) or deoxyribonucleic acid (DNA) when

they reproduce. Normally when a virus infects a cell, an enzyme called

Ribonuclease L (RNase L) is activated and cuts the RNA of the infectious

agent so it cannot replicate itself. The RNase L molecule also cuts the RNA

of the infected cell, which triggers the cell’s death and removal. Then the

RNase L molecule “switches off” and remains inactive so that it doesn’t

damage healthy cells.

Abnormal RNase L Molecule Found in ME/CFS Patients

The normal weight of the RNase L molecule is 80 kilo Daltons (kDa). In

ME/CFS patients, the RNase L molecule is being cut and weighs 37 kDa - less

than half its normal weight. The low molecular weight (LMW) RNase L molecule

can discriminate ME/CFS patients from healthy people, and illnesses such as

Fibromyalgia, multiple sclerosis, cancer, AIDS and depression. The Centers

for Disease Control and Prevention sent 100 blood samples to Dr. De

Meirleir. Using the test for LMW RNase L, Dr. De Meirleir was able to

identify which blood samples came from ME/CFS patients with 99 percent

accuracy. These findings confirm an organic origin of ME/CFS and validate

the diagnosis.

Abnormal RNase L Molecule Causes Chronic Dysfunction of the Immune System

The damaged RNase L molecule is not able to kill infectious agents and it

keeps damaged cells alive. The body is unable to “switch off” these abnormal

RNase L fragments, so they continue to cut the RNA of normal cells. The

destructive RNase L fragment is six times more active than normal and

consumes approximately 70 percent of the cells’ energy (ATP). RNase L

fragments destroy normal protein synthesis, enzyme production, and other

vital cellular functions. They inhibit respiratory muscles, and cause

hyperventilation, metabolic alkalosis, sleep disturbances, and central

fatigue. There is sodium retention, low magnesium levels, and dramatically

low levels of potassium. Natural killer cells, which protect against viruses

and intracellular infections, are also being damaged. Thus, the immune

system is in a state of chronic dysfunction.

Testing for ME/CFS

Dr. De Meirleir is co-founder of REDLABS (www.redlabsusa.com), which

recently opened a lab in Nevada. This lab offers diagnostic and treatment

tests for ME/CFS patients. Although each patient’s profile is unique,

patients tend to fall into three groups with different causes and

treatments. Based on the results of six tests, Dr. De Meirleir was able to

predict patients’ symptoms with 95 percent accuracy while the remaining 5

percent had overlap features. Symptom severity rises in correlation to the

rise in the level of LMW RNase L.

Group Profiles

Group 1: (15 to 20 percent)

This group has high levels of LMW RNase L and elastase, low levels of

protein kinase (PKR) and uric acid, and low to normal levels of nitric

oxide. Spinal taps indicate elevated levels of lymphocytes and proteins in

the spinal fluid, and there is increased pressure upon opening the lumbar

puncture.

These patients have a chronic low-grade viral infection and inflammatory

reaction in the brain. Many micro-organisms are associated with this

profile. Heavy metals, pesticides, and other triggers may also be involved.

Approximately 20 percent of this group has low-grade Herpes Virus 6A (HHV6A)

encephalitis.

The prominent feature is neurocognitive problems such as confusion and

impaired concentration and memory. Fatigue originates in the brain. Pain is

not prominent. Patients exhibit symptoms that have some similarities to

multiple sclerosis (MS).

Group 2: (10 to 15 percent)

These patients have very high levels of LMW RNase L and elastase, high

protein kinase activity, severely low natural killer cell activity, and very

low serum uric acid levels.

This group of severely ill patients has bacterial infections originating

from animals such as pets, rodents, ticks, etc. These patients have severe

bowel problems. The gut is an important part of the immune system because 70

percent of immune cells are in the digestive tract. When a patient has leaky

gut syndrome, the gut has become permeable and foreign proteins enter the

blood and tissues and inflammation results. Dr. De Meirleir tests for 12

pathogenic gut bacteria.

Group 3: (60 to 70 percent)

The majority of ME/CFS patients are in this group. This profile is basically

similar to Group 2, but not as severe. Generalized pain originating from

dysfunction in the pain processing areas of the brain and CNS is a prominent

feature. These patients have gastrointestinal infections, and bacteria are

in the blood.

Some Other Areas of Investigation

Infections

Part of the immune system is activated and part is suppressed, leaving the

patient vulnerable to opportunistic infections. Patients may have one or a

number of infections. Serum Immunobilan tests are done to identify which

ones are active. Suspect microorganisms include viruses, bacteria, and

mycoplasma. A chlamydia pneumonia infection is often found in patients with

chronic sinus infections. Approximately 8 to 10 percent of ME/CFS patients

have infections of animal origin such as Rickettsiae, iella, Bartonella,

and Borrelia. Many of these infections come from pets. A small percentage

come from ticks.

Heavy Metals

Exposure comes from many sources including food, insulation, air, etc.

ME/CFS patients have increased sensitivity to chemicals, environmental

pollutants, and heavy metals, particularly mercury and nickel. Toxins can

trigger an inflammatory response.

One of the RNase L fragments has a structure that is almost identical to a

protein involved in the removal of heavy metals and toxic chemical from

cells. When this protein is blocked by the RNase L fragments, the cells

become more sensitive to mercury. Now a tiny amount of mercury that would

normally kill 10 percent of the cells can kill 50 to 100 percent of the

cells.

Mycrotoxins

Fungi such as Aspergillus Niger and Candida can contribute to ME/CFS

symptoms. Candida is a yeast fungal infection that changes sugars to

aldehydes, a toxic form of alcohol.

Digestive Tract

Gastrointestinal problems are a serious concern in ME/CFS patients: 70

percent of the body’s immune cells are found in the gastrointestinal tract.

These immune cells prevent bacteria and foreign protein from entering the

blood stream. When the gut becomes permeable and foreign protein enters the

blood stream, elastase is produced. Elastase is the enzyme that is

responsible for cutting the RNase L molecule into fragments. Elastase breaks

down elastin, which gives elasticity to collagen. As a result, there is pain

and a loss of elasticity in ligaments and tendons.

Peripheral Resistance to Thyroid Hormone

Most patients have normal results for common thyroid tests. However, ME/CFS

patients have a much higher level of a protein that is 98 percent identical

to T3, which is the active form of thyroid. Because this foreign protein can

bind to T3 receptors, T3 cannot find receptors and is therefore ineffective

in its role of activating cellular metabolism.

Treatment Summary

Some psychiatrists advocate that no tests or lab work be done on ME/CFS

patients because testing will reinforce delusions of physical illness. Given

the wealth of confirmed biochemical abnormalities, such a rationale is

ludicrous. Dr. De Meirleir stressed that tests must be done in order to

determine the origin of the problem. Then treatment can be prescribed to

eliminate the cause. A “clean-up” of all the consequences of the problem

must also be undertaken. Therapies and the order of treatments vary

according to the patient’s unique test profile. Treatment includes:

Restoring immune competence

Removing microorganisms

Restoring hormonal balance

Restoring intestinal flora

Decreasing prostaglandins and protein kinase activity

Removing heavy metals and toxic chemicals.

_____

This summary of Dr. De Meirleir’s lecture, written by Majorie van de Sande,

B Ed, Grad Dip Ed, was reproduced with permission from Quest, the newsletter

of Canada’s National ME/FM Action Network. Ms. van de Sande is the Action

Network’s Advisor and Webmaster, Conference Planning Committee.

Dr. De Meirleir describes various treatment therapies in a full-day

physicians’ workshop, which is available as a set of four DVDs and a CD. For

information about how to order these materials, and a patient workshop in

DVD format, visit the National ME/FM Action Network site, at

www.mefmaction.net

Link to comment
Share on other sites

Join the conversation

You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Loading...
×
×
  • Create New...